Paronychia in association with indinavir treatment.
To assess a possible association between antiretroviral treatment and paronychia, we conducted a retrospective cohort study of 288 human immunodeficiency virus-positive protease inhibitor recipients. Indinavir treatment-adjusted for age, sex, CD4 count, diabetes status and other antiretroviral drug exposures-was significantly associated with paronychia of the great toe (hazard ratio 4.7; 95% confidence interval 1.6-13.9).
Colson
A E
AE
Channing Laboratory and Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Sax
P E
PE
Keller
M J
MJ
Turk
B K
BK
Pettus
P T
PT
Platt
R
R
Choo
P W
PW
D000328:Adult; D000368:Aged; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010304:Paronychia / Q000139:chemically induced* / Q000150:complications; D012189:Retrospective Studies; D019562:Viral Load
D017320:HIV Protease Inhibitors; D019469:Indinavir